Aptose Biosciences Inc.

Posters & Presentations

All Poster Presentation
April 15, 2018 Poster

2018 AACR Poster - CG’806, a first-in-class pan-FLT3/pan-BTK inhibitor, targets multiple pathways to kill diverse subtypes of acute myeloid leukemia and B-cell malignancy in vitro

2018 AACR Poster - CG’806, a first-in-class pan-FLT3/pan-BTK inhibitor, targets multiple pathways to kill diverse subtypes of acute myeloid leukemia and B-cell malignancy in vitro: View Poster
December 11, 2017 Poster

2017 ASH Poster - CG’806, a First-in-Class Pan-FLT3/BTK Inhibitor, Exhibits Potent Growth Inhibition as a Single Agent and in Combination with a BET Bromodomain Inhibitor and a Bcl2 Inhibitor Against AML and CLL Patient Samples

2017 ASH Poster - CG’806, a First-in-Class Pan-FLT3/BTK Inhibitor, Exhibits Potent Growth Inhibition as a Single Agent and in Combination with a BET Bromodomain Inhibitor and a Bcl2 Inhibitor Against AML and CLL Patient Samples: View Poster
December 11, 2017 Poster

2017 ASH Poster - CG’806, a Novel Pan-FLT3/BTK Multi-Kinase Inhibitor, Induces Cell Cycle Arrest, Apoptosis or Autophagy in AML Cells Depending on FLT3 Mutational Status

2017 ASH Poster - CG’806, a Novel Pan-FLT3/BTK Multi-Kinase Inhibitor, Induces Cell Cycle Arrest, Apoptosis or Autophagy in AML Cells Depending on FLT3 Mutational Status: View Poster
December 10, 2017 Poster

2017 ASH Poster - The Pan-FLT3/BTK Multi-Kinase Inhibitor CG’806 Induces AML Killing in FLT-Mutant and Wild Type Cells, and Exerts Synergistic Pro-Apoptotic Effects with Concomitant Targeting of Anti-Apoptotic Bcl-2 and/or Mcl-1

2017 ASH Poster - The Pan-FLT3/BTK Multi-Kinase Inhibitor CG’806 Induces AML Killing in FLT-Mutant and Wild Type Cells, and Exerts Synergistic Pro-Apoptotic Effects with Concomitant Targeting of Anti-Apoptotic Bcl-2 and/or Mcl-1: View Poster
May 7, 2017 Poster

CG’806, a First-in-Class FLT3/BTK Inhibitor, Exhibits Potent Activity Against AML

CG’806, a First-in-Class FLT3/BTK Inhibitor, Exhibits Potent Activity Against AML: View Poster
May 7, 2017 Poster

CG’806, a First‐in‐Class FLT3/BTK Inhibitor, Exerts Superior Potency Against AML Cells Harboring FLT3‐ITD, TKD, and Gatekeeper Mutant or Wild‐Type FLT3

CG’806, a First‐in‐Class FLT3/BTK Inhibitor, Exerts Superior Potency Against AML Cells Harboring FLT3‐ITD, TKD, and Gatekeeper Mutant or Wild‐Type FLT3: View Poster
December 3, 2016 Poster

ASH Poster

ASH Poster: View Poster
December 6, 2015 Poster

ASH Poster 2015

ASH Poster 2015: View Poster
December 5, 2015 Poster

Broad Activity of APTO-253 in AML and Other Hematologic Malignancies Correlates with KLF4 Expression Level

Broad Activity of APTO-253 in AML and Other Hematologic Malignancies Correlates with KLF4 Expression Level: View Poster